{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["de Bray A"],"funding":["RCUK | Engineering and Physical Sciences Research Council (EPSRC)","Novo Nordisk Fonden (Novo Nordisk Foundation)","Novo Nordisk","RCUK | MRC | Medical Research Foundation","Medical Research Council","Diabetes UK","EC | EU Framework Programme for Research and Innovation H2020 | H2020 Excellent Science (H2020 Priority Excellent Science)","European Foundation for the Study of Diabetes (EFSD)","Royal Society","Wellcome Trust","Biotechnology and Biological Sciences Research Council"],"pagination":["1536-1549"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12373499"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["7(8)"],"pubmed_abstract":["Dual agonists targeting glucagon-like peptide-1 receptor (GLP1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) are breakthrough treatments for patients with type 2 diabetes and obesity. Compared to GLP1R agonists, dual agonists show superior efficacy for glucose lowering and weight reduction. However, delineation of dual agonist cell targets remains challenging. Here, we develop and test daLUXendin and daLUXendin+, non-lipidated and lipidated fluorescent GLP1R/GIPR dual agonist probes, and use them to visualize cellular targets. daLUXendins are potent GLP1R/GIPR dual agonists that advantageously show less functional selectivity for mouse GLP1R over mouse GIPR. daLUXendins label rodent and human pancreatic islet cells, with a signal intensity of β cells > α cells = δ cell"],"journal":["Nature metabolism"],"pubmed_title":["Fluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain."],"pmcid":["PMC12373499"],"funding_grant_id":["N/A","22/0006389","EP/X026833/1","23/0006627","MRC_MC_UU_12012/3","220271/Z/20/Z","NN-Oxford Fellowship","MR/Y00132X/1","23/0006509","101042046","17/0005681","INF/R2/212001","MR/W000881/2","MR/X003604/1","715884","BB/W014831/1"],"pubmed_authors":["Viloria K","Armour S","Ast J","Ammala C","Owen DM","Nieves DJ","Roßmann K","Trott JPP","Reimann F","Adriaenssens AE","Jones B","Soykan T","Roberts AG","Shilleh AH","Broichhagen J","Jiang W","Tomlinson JW","Tong J","de Bray A","Pearce A","Huhn C","Trapp S","Hodson DJ","Cyranka M","Figueredo Burgos NS","Epanchintsev A","Nasteska D","Ladds G","Miyazaki S","Gatin-Fraudet B"],"additional_accession":[]},"is_claimable":false,"name":"Fluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain.","description":"Dual agonists targeting glucagon-like peptide-1 receptor (GLP1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) are breakthrough treatments for patients with type 2 diabetes and obesity. Compared to GLP1R agonists, dual agonists show superior efficacy for glucose lowering and weight reduction. However, delineation of dual agonist cell targets remains challenging. Here, we develop and test daLUXendin and daLUXendin+, non-lipidated and lipidated fluorescent GLP1R/GIPR dual agonist probes, and use them to visualize cellular targets. daLUXendins are potent GLP1R/GIPR dual agonists that advantageously show less functional selectivity for mouse GLP1R over mouse GIPR. daLUXendins label rodent and human pancreatic islet cells, with a signal intensity of β cells > α cells = δ cell","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-05-08T06:54:18.751Z","creation":"2026-04-07T23:30:28.285Z"},"accession":"S-EPMC12373499","cross_references":{"pubmed":["40830598"],"doi":["10.1038/s42255-025-01342-6"]}}